Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2013 Apr 29;14(5):9408–9423. doi: 10.3390/ijms14059408

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2013 by the authors; licensee MDPI, Basel, Switzerland

This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).

PMC Copyright notice

Vasodilation induced by the supernatant from stimulated cardiac myocytes. The supernatant of electrically stimulated cardiac myocytes dilated WT coronary arterioles dose-dependently. Vasodilation with WT cardiac myocyte supernatant was more potent compared to that with SMP30 KO cardiac myocyte supernatant (A) Administration of olmesartan to coronary arterioles enhanced vasodilation in the SMP30 KO cardiac myocyte supernatant treatment group (500 μL of supernatant). Administration of catalase to coronary arterioles converted vasodilation to vasoconstriction in the SMP30 KO cardiac myocyte supernatant treatment group and eliminated vasodilation in the WT cardiac myocyte supernatant treatment group. Treatment with olmesartan in addition to catalase in the vessel bath eliminated vasoconstriction in the SMP 30 KO cardiac myocyte supernatant treatment group; (B) Values are expressed as the mean ± S.E.M. n = 12 each, * p < 0.01 vs. without agent.

Vasodilation induced by the supernatant from stimulated cardiac myocytes. The supernatant of electrically stimulated cardiac myocytes dilated WT coronary arterioles dose-dependently. Vasodilation with WT cardiac myocyte supernatant was more potent compared to that with SMP30 KO cardiac myocyte supernatant (A) Administration of olmesartan to coronary arterioles enhanced vasodilation in the SMP30 KO cardiac myocyte supernatant treatment group (500 μL of supernatant). Administration of catalase to coronary arterioles converted vasodilation to vasoconstriction in the SMP30 KO cardiac myocyte supernatant treatment group and eliminated vasodilation in the WT cardiac myocyte supernatant treatment group. Treatment with olmesartan in addition to catalase in the vessel bath eliminated vasoconstriction in the SMP 30 KO cardiac myocyte supernatant treatment group; (B) Values are expressed as the mean ± S.E.M. n = 12 each, * p < 0.01 vs. without agent.